Page 8 - Eceptor News Today

NewsMedical speaks with Chao Ma, Ph.D. a Research Assistant Professor at New York University Tandon School of Engineering, ahead of his presentation at SLAS 2024.

A common test used to decide whether breast cancer patients should get chemotherapy may be making bad recommendations for some Black women, leading them to forgo chemotherapy when it might have helped, according to new research from the University of Illinois Chicago.

According to a study led by researchers at Washington University School of Medicine in St. Louis, diagnoses of breast cancer have increased steadily in women under age 50 over the past two decades, with steeper increases in more recent years.

A multi-institutional study co-authored by University of Texas at Arlington scientists uncovered a mechanism by which cancer cells prevent the immune system from activating and attacking the cancerous invaders.

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, "Systematic analysis of the prognostic value and immunological function of LTBR in human cancer."

A team led by LMU researchers Christian Weber and Yvonne Döring has demonstrated new mechanisms that are involved in the development of inflammatory cardiovascular diseases.

Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic liver disease, according to a nationwide study from Karolinska Institutet in Sweden published in the journal Gut.

Rutgers researchers can predict which patients will benefit from a popular prostate cancer drug – and have devised a strategy that may make the treatment work longer.

A team of scientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory and Columbia University has demonstrated a way to produce large quantities of the receptor that SARS-CoV-2, the virus that causes COVID-19, binds to on the surface of human cells.

Researchers have identified a receptor protein known as CHRM1 as a key player in prostate cancer cells' resistance to docetaxel, a commonly used chemotherapy drug to treat advanced cancer that has spread beyond the prostate.